Last updated: July 28, 2025
Introduction
Synjardy is a prescription medication indicated for adult patients with type 2 diabetes mellitus, combining two active ingredients: empagliflozin and metformin. Developed by Boehringer Ingelheim and Eli Lilly and Company, Synjardy offers a synergistic approach to glycemic control. As a combination drug, its supply chain encompasses a complex network of raw material providers, active pharmaceutical ingredient (API) manufacturers, formulation facilities, and distribution channels. This analysis explores the primary suppliers involved in the production and distribution of Synjardy, examining their roles, strategic significance, and the implications of their partnerships within the pharmaceutical supply chain.
Active Pharmaceutical Ingredient (API) Suppliers
1. Empagliflozin Suppliers
Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, first approved by the U.S. Food and Drug Administration (FDA) in 2014. Its synthesis involves complex chemical reactions, necessitating high-quality chemical intermediates sourced globally.
Major API Manufacturers:
-
Hetero Labs (India): One of the leading suppliers of empagliflozin API, Hetero has established robust manufacturing processes for SGLT2 inhibitors, including empagliflozin. Their facilities comply with Good Manufacturing Practices (GMP), crucial for active ingredients intended for chronic conditions like diabetes.
-
Samsung Bioepis (South Korea): Engaged in API production, Samsung Bioepis supplies high-purity empagliflozin that meets stringent quality standards to pharmaceutical companies worldwide.
-
Celltrion (South Korea): Although primarily known for biosimilars, Celltrion has diversified into chemical synthesis, including APIs like empagliflozin, contributing to the supply diversity and competitive pricing.
Supply Dynamics:
Empagliflozin APIs are predominantly sourced from Indian and South Korean manufacturers, driven by cost efficiencies, expertise, and capacity. The APIs must meet regulatory standards, including EMA and FDA compliance, ensuring batch-to-batch consistency.
2. Metformin Suppliers
Metformin is one of the most widely prescribed antidiabetic agents, with a well-established manufacturing ecosystem.
Primary Suppliers:
-
Cambridge Commodities (UK): Offers high-quality metformin HCl suitable for API manufacturing and formulation intermediates.
-
Lupin Ltd. (India): One of the world’s largest producers of metformin, Lupin has extensive manufacturing capacity, meeting global regulatory standards. Their processes generally involve environmentally friendly synthesis with high purity levels.
-
Teva Pharmaceuticals (Israel): Supplies metformin APIs globally, leveraging advanced synthetic routes and rigorous quality controls.
Supply Considerations:
The metformin supply chain benefits from decades of established manufacturing practices, with key sources in India and Israel. The global demand ensures diverse suppliers, safeguarding against shortages and price fluctuations.
Formulation & Final Product Manufacturing
1. Contract Manufacturing Organizations (CMOs)
Synjardy’s final formulation involves blending empagliflozin and metformin in controlled dosages, then encapsulating or tablet-compressing the mixture.
-
Boehringer Ingelheim's Manufacturing Facilities (Germany and the USA): Responsible for formulation, blending, and tablet compression of Synjardy, ensuring compliance with regulatory standards.
-
Eli Lilly’s Contract Manufacturing Partners: Conduct formulation and packaging, leveraging global CMO networks, especially in India and Europe.
2. Packaging and Distribution
Post-production, Synjardy tablets are packaged in blister packs or bottles, then distributed globally.
-
Autonomous Packaging Units: Located within manufacturing plants or through third-party packaging specialists, these units adhere to serialization and anti-counterfeiting standards.
-
Distribution Networks: Distributed through authorized wholesalers, pharmacies, hospitals, and managed-care organizations, with logistical partners spanning global logistics providers including DHL, FedEx, and specialized pharmaceutical logistics firms.
Key Suppliers and Strategic Partnerships
1. Raw Material and API Suppliers
The robustness of Synjardy’s supply chain hinges on the diversified API sourcing from reputable manufacturers in India, South Korea, and Israel, ensuring cost competitiveness and supply security. Their GMP compliance and proactive quality assurance are vital.
2. Contract Manufacturing Organizations
Boehringer Ingelheim and Eli Lilly’s reliance on contracted facilities emphasizes strategic partnerships emphasizing quality, regulatory compliance, and capacity expansion, especially in emerging markets.
3. Quality Assurance and Regulatory Compliance
Suppliers must adhere to strict quality standards, including FDA, EMA, and other regional authorities, to ensure the safety and efficacy of the final product. Regulatory filings and continuous supply depend on maintaining these standards.
Supply Chain Risks and Management
-
Regulatory Changes: Shifts in global pharmaceutical regulations may affect supplier approvals, requiring continuous compliance monitoring.
-
Supply Disruptions: Dependence on API suppliers from India and South Korea exposes the supply chain to geopolitical, natural disaster, or pandemic-related disruptions, necessitating redundancy and inventory management.
-
Price Volatility: Raw material prices can fluctuate, affecting manufacturing costs. Long-term contracts and supplier diversification help mitigate this risk.
Conclusion
Synjardy’s supply chain comprises a strategic network of global API suppliers—primarily from India and South Korea—forming the backbone of its manufacturing process. Boehringer Ingelheim and Eli Lilly leverage robust partnerships with multiple API manufacturers and CMOs to ensure consistent quality and supply security. The bio-pharmaceutical landscape continues to evolve, with regulatory compliance and supply chain resilience remaining critical success factors.
Key Takeaways
- Diversified API sourcing from India (Lupin, Hetero) and South Korea (Samsung, Celltrion) mitigates supply risks and ensures competitive pricing.
- Robust manufacturing partnerships with CMOs facilitate large-scale formulation, packaging, and distribution, maintaining regulatory compliance.
- Regulatory adherence and quality assurance are vital for maintaining product integrity, especially amidst global supply chain challenges.
- Supply chain risks from geopolitical issues and natural disasters necessitate contingency planning, including inventory buffering and supplier diversification.
- Emerging markets present both opportunities for expansion and challenges related to regulatory compliance and logistical complexities.
FAQs
1. Who are the main API suppliers for empagliflozin used in Synjardy?
Major suppliers include Hetero Labs (India), Samsung Bioepis (South Korea), and Celltrion (South Korea). These companies manufacture high-purity empagliflozin compliant with international standards.
2. How is metformin sourced for Synjardy's production?
Leading suppliers include Lupin Ltd. (India), Teva Pharmaceuticals (Israel), and Cambridge Commodities (UK), which supply quality metformin APIs globally.
3. What manufacturing standards must API suppliers meet for Synjardy?
Suppliers must adhere to GMP regulations, with certifications from agencies like the FDA and EMA, ensuring consistent quality and safety.
4. How does supply chain risk impact Synjardy's availability?
Disruptions in API supply, geopolitical issues, or natural disasters can lead to shortages, emphasizing the importance of diversified sourcing and inventory management.
5. Are there plans to localize manufacturing or diversify suppliers further?
While current strategies focus on diversification, ongoing assessments aim to include alternative suppliers and potentially establish regional manufacturing hubs to enhance supply resilience.
Sources
- U.S. Food and Drug Administration (FDA). Empagliflozin approval information. 2014.
- European Medicines Agency (EMA). SGLT2 inhibitors overview. 2022.
- Lupin Ltd. Annual report on manufacturing capacity and compliance.
- Boehringer Ingelheim and Eli Lilly official disclosures on manufacturing partnerships and supply chain management.
- Market analysis reports on pharmaceutical raw material suppliers in India and South Korea.
